JPRN-jRCT2080221601未知1 期
ONO-6950 Phase 1 Study (Single-dose and multiple-dose, oral administration)
ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 52 人开始时间: 2011年9月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 35age old（—）
- 性别
- Male
入选标准
- •1. Japanese healthy adult
- •2. BMI of 18.5=< <25kg/m2
排除标准
- •1. Subject who has history or presence of clinically significant respiratory/pulmonary, cardiovascular, neurologic, psychiatric, digestive, hepatic, renal, hematopoietic, endocrine/metabolic diseases or disorders, and who is disqualified from the study at the discretion of primary investigator or sub-investigator.
研究者
相似试验
未知
1 期
ONO-6950 Phase I StudyAsthmaJPRN-jRCT2080221411ONO PHARMACEUTICAL CO.,LTD.56
已完成
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult SubjectsHealthy Adult SubjectsNCT01297582Ono Pharma USA Inc56
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult SubjectsHealthy Adult SubjectsNCT01405651Ono Pharma USA Inc24
进行中（未招募）
1 期
Glioblastoma treatment with irradiation and olaptesed pegol in unmethylated patientsglioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004064-62-DEOXXON Pharma AG27
未知
1 期
Phase 1 study of ONO-7056Solid tumorJPRN-jRCT2080221709ONO PHARMACEUTICAL CO.,LTD.36